StonvexLoading…
StonvexStonvexStonvexCore line items from NCLH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $9.83B | $9.48B | $8.55B | $4.84B |
Operating Income | $1.56B | $1.47B | $930.91M | $-1.55B |
Net Income | $423.25M | $910.26M | $166.18M | $-2.27B |
EPS (Diluted) | $0.92 | $1.89 | $0.39 | $-5.41 |
Total Assets | $22.54B | $19.97B | $19.49B | $18.56B |
Total Liabilities | $20.33B | $18.54B | $19.19B | $18.49B |
Cash & Equivalents | $209.89M | $190.76M | $402.42M | $946.99M |
Free Cash Flow OCF − CapEx | $-1.17B | $838.87M | $-744.65M | $-1.57B |
Shares Outstanding | 455.26M | 439.86M | 425.55M | 421.41M |